---
title: "Johnson & Johnson plans to acquire a cancer therapy research company for over $3 billion"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/266222307.md"
description: "Johnson & Johnson announced on Monday that it will acquire the private company Halda Therapeutics for $3.05 billion in cash, thereby expanding its business in the field of solid tumors and prostate cancer treatment. Halda's leading candidate drug HLD-0915 is currently in the early to mid-stage development for the treatment of prostate cancer, and the company also has several early experimental therapies targeting breast cancer, lung cancer, and other types of tumors. Johnson & Johnson expects the transaction to be completed in the coming months"
datetime: "2025-11-17T13:51:04.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/266222307.md)
  - [en](https://longbridge.com/en/news/266222307.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/266222307.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/266222307.md) | [繁體中文](https://longbridge.com/zh-HK/news/266222307.md)


# Johnson & Johnson plans to acquire a cancer therapy research company for over $3 billion

Johnson & Johnson (JNJ.US) announced on Monday that it will acquire the private company Halda Therapeutics for $3.05 billion in cash, thereby expanding its business in the field of solid tumors and prostate cancer treatment.

Halda's leading candidate drug HLD-0915 is currently in the early to mid-stage development for the treatment of prostate cancer, and the company also has several early experimental therapies targeting breast cancer, lung cancer, and other types of tumors. Johnson & Johnson expects the transaction to be completed in the coming months

### Related Stocks

- [Johnson & Johnson (JNJ.US)](https://longbridge.com/en/quote/JNJ.US.md)

## Related News & Research

- [J&J’s Darzalex nets first self-administered cancer injectable approval](https://longbridge.com/en/news/280822205.md)
- [Daratumumab becomes first oncology injectable approved for patient administration](https://longbridge.com/en/news/280990101.md)
- [Cardinal Health Boosts Actinium-225 Production Capacity to Meet Demand for Novel Cancer Therapies](https://longbridge.com/en/news/281360890.md)
- [AstraZeneca’s rare disease unit posts positive Phase III data for new hypophosphatasia therapy](https://longbridge.com/en/news/281133098.md)
- [Orser Capital Management LLC Purchases Shares of 5,217 Johnson & Johnson $JNJ](https://longbridge.com/en/news/280872064.md)